# A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

> **NCT03958877** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Biogen** · enrollment: 152 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** BIIB017 (peginterferon beta-1a)
- **DRUG:** Interferon beta type 1a

## Key facts

- **NCT ID:** NCT03958877
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-18
- **Primary completion:** 2027-05-20
- **Final completion:** 2027-05-20
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03958877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03958877, "A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03958877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*